The Presbyopia drugs in development market research report provides comprehensive information on the therapeutics under development for Presbyopia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Presbyopia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Presbyopia and features dormant and discontinued products.

GlobalData tracks 26 drugs in development for Presbyopia by 22 companies/universities/institutes. The top development phase for Presbyopia is preclinical with nine drugs in that stage. The Presbyopia pipeline has 26 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Presbyopia pipeline products market are: Ocuphire Pharma, Lenz Therapeutics and Cellix Bio.

The key targets in the Presbyopia pipeline products market include Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM), Alpha 2 Adrenergic Receptor (ADRA2), and Alpha 1 Adrenergic Receptor (ADRA1).

The key mechanisms of action in the Presbyopia pipeline product include Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM) Agonist with seven drugs in Phase III. The Presbyopia pipeline products include two routes of administration with the top ROA being Ophthalmic and one key molecule types in the Presbyopia pipeline products market including Small Molecule.

Presbyopia overview

Presbyopia is an eye condition in which the eyes slowly lose the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eye strain, difficulty reading small print, and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis, and eye trauma.

For a complete picture of Presbyopia’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.